AML   

Does your answer change based on clinical or molecular risk factors, and if so how? Does your answer change if MRD status after induction is unknown?

Is there any data on combining the two?

Is there a role for non-myeloablative regimens?

Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?

How does graft source, conditioning regimen, and indication for transplant affect your decision regarding G-CSF?

NGS results are pending

Would you test for bone marrow failure syndromes before beginning the conditioning regimen?

Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?

If not, what instructions do you give to patients regarding checking temperature at home/return precautions?

It used to be a contraindication for G-CSF use for AML patients, but currently, several protocols include it to decrease neutropenic duration.

Patient treated per AAML0531

Particular patient is s/p 2 HSCTs

Many patients have had prior chemotherapy exposure with newly diagnosed AML that may not have classic therapy-related cytogenetics.  How do you a...

Or do you use prophylactic defibrotide?

I have heard <20% MRD. What about proceeding if patient is hypoplastic after chemotherapy?

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

Should the goal always be to proceed to a second transplant? 

Would you consider “bridging” therapy with something like an HMA?

Does acute leukemia sub-type affect your decision? 

What is your preferred treatment?

Can it be added after 2 or 3 cycles of HMA?